Today: 29 January 2026
Subscribe
Browse Category

Pharma Industry News 13 January 2026 - 22 January 2026

Novo Nordisk stock rebounds after a bruising drop as investors turn to the next catalyst

Novo Nordisk stock rebounds after a bruising drop as investors turn to the next catalyst

COPENHAGEN, Jan 22, 2026, 13:34 CET — Regular session Novo Nordisk shares rose 4.3% to 389.95 Danish crowns by 1318 CET on Thursday, recovering most of a steep slide the day before. (Google) The move comes after a volatile run in Copenhagen, with the stock falling about 4% on Wednesday after a 3% rise the previous session, data showed. (Investing)…
22 January 2026
·····
AbbVie stock rises after-hours as Bernstein sticks with $225 target ahead of Feb. 4 earnings

AbbVie stock rises after-hours as Bernstein sticks with $225 target ahead of Feb. 4 earnings

New York, January 21, 2026, 18:56 EST — After-hours AbbVie Inc. shares climbed 0.99% to $216.15 Wednesday, fluctuating between $211.57 and $218.00 during the session. After-hours trading saw little movement. Around 10.7 million shares exchanged hands, matching the drugmaker’s typical volume. (StockAnalysis) The timing is crucial as AbbVie approaches its full-year and fourth-quarter earnings report in two weeks. So far,…
22 January 2026
·····
ImmunityBio stock jumps before the open after FDA outlines next step for ANKTIVA filing

ImmunityBio stock jumps before the open after FDA outlines next step for ANKTIVA filing

New York, January 20, 2026, 08:14 (EST) — Premarket ImmunityBio (IBRX.O) shares rose about 27% to $7 in premarket trading on Tuesday, with about 4.1 million shares changing hands, after the company said it had made progress with the U.S. Food and Drug Administration on a path to revive a label-expansion push for its bladder cancer treatment ANKTIVA. (Public) The…
20 January 2026
·····
Roche stock in focus: Goldman flips to Neutral, UBS lifts target as Jan 29 results loom

Roche stock in focus: Goldman flips to Neutral, UBS lifts target as Jan 29 results loom

Zurich, Jan 18, 2026, 17:32 CET — Market closed Roche Holding Ltd’s non-voting shares ended Friday up 0.93%, closing at 348.90 Swiss francs. The stock has remained within a narrow band heading into Monday’s session. (MarketScreener) Goldman Sachs upgraded Roche from “sell” to “neutral” and boosted its 12-month price target to 365 Swiss francs, up from 260. The bank highlighted…
18 January 2026
·····
ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next

ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next

New York, Jan 17, 2026, 06:10 EST — Markets have closed for the day. Shares of ImmunityBio Inc (IBRX.O) surged almost 40% on Friday following a strong boost in preliminary sales for its bladder cancer treatment ANKTIVA, alongside fresh trial updates. The stock finished at $5.52, marking a 39.9% gain, after swinging between $4.09 and $6.44 on heavy volume of…
17 January 2026
·····
BridgeBio Pharma (BBIO) stock edges up after $550 million convertible notes pricing — what investors watch next

BridgeBio Pharma (BBIO) stock edges up after $550 million convertible notes pricing — what investors watch next

New York, January 16, 2026, 14:57 EST — Regular session Shares of BridgeBio Pharma Inc edged up 0.5% to $76.66 Friday afternoon, following the announcement of a $550 million convertible notes sale. The stock swung between $75.87 and $78.12, with roughly 5.9 million shares changing hands. (BridgeBio Investor Relations) This financing matters because it reshapes BridgeBio’s balance sheet in one…
16 January 2026
·····
ImmunityBio stock jumps in premarket as $113 mln ANKTIVA sales update fuels rally

ImmunityBio stock jumps in premarket as $113 mln ANKTIVA sales update fuels rally

New York, January 16, 2026, 05:00 (EST) — Premarket ImmunityBio, Inc. shares jumped roughly 32% to $3.95 in premarket trading Friday following the biotech’s report of a steep rise in preliminary 2025 product revenue. The company also highlighted recent regulatory approvals in Saudi Arabia. (Business Wire) The update offers investors an early glimpse of how quickly ANKTIVA is growing commercially,…
16 January 2026
····
Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom

Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom

New York, January 14, 2026, 14:54 EST — During regular session Shares of Praxis Precision Medicines jumped roughly 8% on Wednesday, bucking the weaker trend in the broader market. By mid-afternoon, the Nasdaq-listed biotech was trading at $303.23, up $22.40. The move came after Praxis announced late Tuesday it hired epilepsy expert Dr. Orrin Devinsky for a new head of…
14 January 2026
····
Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

New York, January 14, 2026, 13:09 EST — Regular session underway. Shares of Viking Therapeutics climbed roughly 11% on Wednesday, rising from a $30.44–$34.08 range to $34.06 by 1:09 p.m. EST. The move came amid renewed deal speculation in obesity treatments. CEO Brian Lian noted that interest was “broader than is visible” with more players “circling around the space.” Analysts…
14 January 2026
····
Thermo Fisher Scientific stock rises on reshoring contract talk, Nvidia lab deal and exec shuffle

Thermo Fisher Scientific stock rises on reshoring contract talk, Nvidia lab deal and exec shuffle

New York, Jan 14, 2026, 12:49 ET — Regular session Shares of Thermo Fisher Scientific (NYSE: TMO) climbed 1.4% to $615.46 Wednesday after CEO Marc Casper announced that the company’s pharma services division secured contracts linked to “reshoring” — shifting drug manufacturing back from Europe and Asia to the U.S. Speaking at the J.P. Morgan Healthcare Conference, Casper highlighted “a…
14 January 2026
·····
Harmony Biosciences stock drops after ZYN002 exit as 2026 Wakix sales outlook tops $1 billion

Harmony Biosciences stock drops after ZYN002 exit as 2026 Wakix sales outlook tops $1 billion

NEW YORK, Jan 13, 2026, 16:19 EST — After-hours Shares of Harmony Biosciences Holdings Inc (HRMY) slid 6.4% on Tuesday to close at $35.82, after trading as low as $34.69. The move comes as investors work through a pipeline reshuffle and a new revenue outlook that landed just as healthcare executives crowd into San Francisco for the annual J.P. Morgan…
13 January 2026
·····
AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

New York, January 13, 2026, 14:45 ET — Regular session AbbVie shares slipped 0.1% to $219.83 Tuesday afternoon after the drugmaker announced a three-year deal with the Trump administration. The pact aims to lower certain drug prices in return for exemptions from tariffs and future pricing rules. The deal arrives amid investor attempts to figure out how “lower prices” might…
13 January 2026
·····
1 2 3 … 8

Stock Market Today

  • Bharti Hexacom Stock Falls 18% Despite Strong 25% ROE and Robust Earnings Growth
    January 28, 2026, 9:53 PM EST. Bharti Hexacom Limited's stock has dropped 18% over three months, yet its fundamentals remain strong. The company's return on equity (ROE), a measure of profitability relative to shareholder investments, stands at 25%, well above the industry average of 13%. This indicates efficient capital use by management. Over the past five years, Bharti Hexacom achieved net income growth of 28%, outperforming the industry average of 5.3%. Such growth and profit retention suggest potential for continued expansion. Investors weighing the stock should consider if this strong earnings momentum is already reflected in the current share price before deciding on its future outlook.
Go toTop